SCHEMBL10008025

SCHEMBL10008025

CN(C)C(=O)n1c(=O)n(C)c2cnc(CCc3ccc(F)cc3)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP1 O94782 7/20 0.40
▸ MAOB P27338 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ CYP1A2 P05177 3/20 0.37
▸ CYP3A4 P08684 3/20 0.37
▸ CYP2C9 P11712 3/20 0.37
▸ TSHR P16473 3/20 0.37
▸ CYP2C19 P33261 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CASP7 P55210 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ BRCA1 P38398 1/20 0.37
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10006652 0.90 USP1 (0.39) USP1MAOBDAGLATSPO
SCHEMBL10007126 0.89 GRIN2B (0.41) USP1ALDH1A1CYP1A2CASP7MEN1
SCHEMBL10007233 0.88 ALDH1A1 (0.36) USP1MAOBALDH1A1CYP1A2CYP3A4
SCHEMBL10006348 0.88 CYP3A4 (0.38) USP1ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL10260978 0.86 USP1 (0.39) USP1GRIN1GRIN2B
SCHEMBL10006670 0.85 USP1 (0.40) USP1
SCHEMBL10261340 0.83 DAGLA (0.45) USP1MAOBALDH1A1TSHRMEN1
SCHEMBL10261859 0.83 DAGLA (0.47) USP1MAOBALDH1A1TSHRMEN1
SCHEMBL10006357 0.82 GRIN2B (0.37) USP1MAOBALDH1A1MAOAGRIN1
SCHEMBL10006583 0.82 ALDH1A1 (0.36) USP1MAOBALDH1A1MAOAGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 — — EP claimed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US claimed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 — — EP claimed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US claimed
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 — — EP disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 — — EP disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE FAAH, FAAH2, TPMT USP1 1070/4885MAOB 15/4885ALDH1A1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback